Financial News
Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX )
2.230
+0.010
(+0.45%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
All News about Amylyx Pharmaceuticals, Inc. - Common Stock
![](https://mms.businesswire.com/media/20230615926630/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
![](https://g.foolcdn.com/editorial/images/735665/buy-dice.jpg)
![](https://mms.businesswire.com/media/20230606005053/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
![](/next-assets/images/schema-image-default.png)
7 Analysts Have This to Say About Amylyx Pharma
May 31, 2023
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Analyst Expectations for Amylyx Pharma's Future
May 15, 2023
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Amylyx Pharma Earnings Preview
May 10, 2023
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Analyst Ratings for Amylyx Pharma
March 31, 2023
Via Benzinga
![](https://www.investors.com/wp-content/uploads/2022/02/Stock-biohavenpharma-01-adobe.jpg)
![](https://mms.businesswire.com/media/20230530005232/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
![](https://www.marketbeat.com/logos/articles/med_20230516052439_amylyx-pharmaceuticals-turns-profitable-on-success.jpg)
![](https://g.foolcdn.com/editorial/images/732401/dna-double-helix.jpg)
![](/next-assets/images/schema-image-default.png)
Expert Ratings for Amylyx Pharma
March 31, 2023
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Via Benzinga
![](/next-assets/images/schema-image-default.png)
Analyst Expectations for Amylyx Pharma's Future
March 14, 2023
Via Benzinga
![](https://g.foolcdn.com/editorial/images/724617/happy-investor.jpg)
![](/next-assets/images/schema-image-default.png)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/stock_charts_2_3.png?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2018/12/Stock-DrugDesigner-01-adobe.jpg)
![](https://mms.businesswire.com/media/20230511005805/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
![](https://mms.businesswire.com/media/20230504005006/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
![](https://g.foolcdn.com/editorial/images/729619/ma.jpg)
![](https://mms.businesswire.com/media/20230420005326/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
![](https://mms.businesswire.com/media/20230413005192/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
![](https://mms.businesswire.com/media/20230411005241/en/802420/5/13268_Amylyx_logo_notagline-Color.jpg)
![](https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600.png)
![](/next-assets/images/schema-image-default.png)
Via Benzinga
![](https://www.investors.com/wp-content/uploads/2023/03/Stock-FirstRepublic-cali-shut.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.